Mankind Pharma Ltd

Mankind Pharma Ltd

₹ 2,186 -0.15%
22 Feb 2:23 p.m.
About

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leading Pharmaceutical company[1] Mankind is India’s 4th largest pharmaceutical company in terms of Domestic Sales and 3rd largest in terms of sales volume for Moving Annual Total (“MAT”) December 2022.

  • Market Cap 87,585 Cr.
  • Current Price 2,186
  • High / Low 2,297 / 1,241
  • Stock P/E 53.0
  • Book Value 216
  • Dividend Yield 0.00 %
  • ROCE 20.7 %
  • ROE 17.0 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 10.1 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,645 2,061 2,258 1,936 1,872 2,300 2,453 2,359
1,336 1,641 1,735 1,563 1,491 1,761 1,818 1,755
Operating Profit 309 420 522 374 381 539 635 603
OPM % 19% 20% 23% 19% 20% 23% 26% 26%
8 19 69 32 42 57 58 67
Interest 11 9 8 9 1 2 4 4
Depreciation 36 65 66 71 67 69 77 90
Profit before tax 270 365 517 326 355 526 612 576
Tax % 20% 18% 19% 24% 21% 22% 23% 15%
217 298 420 249 281 409 473 487
EPS in Rs 5.43 7.44 10.49 6.21 7.01 10.22 11.80 12.16
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
3,918 3,829 4,794 5,523 7,486 8,127 8,984
3,141 3,124 3,550 4,151 5,644 6,429 6,825
Operating Profit 778 705 1,244 1,372 1,842 1,698 2,159
OPM % 20% 18% 26% 25% 25% 21% 24%
209 64 94 154 200 163 225
Interest 18 40 11 8 48 28 11
Depreciation 28 38 62 78 123 270 303
Profit before tax 941 691 1,265 1,440 1,871 1,563 2,070
Tax % 26% 26% 24% 25% 26% 20%
694 514 958 1,084 1,389 1,248 1,650
EPS in Rs 17.33 12.83 23.92 27.07 34.68 31.16 41.19
Dividend Payout % 0% 0% 32% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 16%
3 Years: 19%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: 12%
3 Years: 9%
TTM: 39%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 22%
3 Years: 21%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 40 40 40 40 40 40 40
Reserves 2,957 3,025 3,611 4,694 6,500 7,744 8,631
360 190 3 101 688 5 10
652 596 877 1,045 1,710 1,583 1,883
Total Liabilities 4,009 3,851 4,531 5,880 8,939 9,371 10,564
534 778 945 987 2,927 3,142 3,531
CWIP 322 211 148 166 387 495 92
Investments 1,402 1,698 1,784 2,397 2,526 3,102 3,885
1,751 1,164 1,655 2,330 3,100 2,632 3,056
Total Assets 4,009 3,851 4,531 5,880 8,939 9,371 10,564

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
540 537 960 983 821 1,799
-516 -306 -396 -1,127 -1,360 -1,041
8 -240 -559 89 579 -710
Net Cash Flow 31 -9 5 -55 40 48

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 23 13 32 24 23 22
Inventory Days 120 126 124 169 183 132
Days Payable 115 101 113 122 133 103
Cash Conversion Cycle 27 38 43 72 73 52
Working Capital Days 95 44 41 49 60 40
ROCE % 22% 36% 33% 30% 21%

Shareholding Pattern

Numbers in percentages

33 Recently
Jun 2023Sep 2023Dec 2023
76.50% 76.50% 76.50%
4.18% 4.18% 6.74%
4.65% 4.56% 9.78%
14.67% 14.76% 6.97%
No. of Shareholders 1,31,9181,34,7311,27,449

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents